Stocktoria
Merck KGaA MRK.DE
DE · Deutsche Börse Xetra · XETR · stock · Healthcare · website
Merck KGaA financials (annual, from 10-K)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $21.1B | $21.2B | $21.0B | $22.2B |
| Gross profit | $12.3B | $12.5B | $12.4B | $13.7B |
| R&D expense | $2.4B | $2.3B | $2.4B | $2.5B |
| SG&A expense | $5.5B | $5.4B | $5.3B | $5.4B |
| Operating income | $3.7B | $4.0B | $3.6B | $4.8B |
| Interest expense | $386.0M | $292.0M | $321.0M | $235.0M |
| Income tax | $693.0M | $751.0M | $650.0M | $948.0M |
| Net income | $2.6B | $2.8B | $2.8B | $3.3B |
| EPS (diluted) | $6.00 | $6.39 | $6.49 | $7.65 |
| Operating cash flow | $3.9B | $4.6B | $3.8B | $4.3B |
| Free cash flow | $2.0B | $2.4B | $1.8B | $2.5B |
| Cash & equivalents | $2.3B | $2.1B | $1.6B | $1.4B |
| Inventory | $4.6B | $4.5B | $4.6B | $4.6B |
| Total assets | $51.5B | $51.6B | $48.5B | $48.5B |
| Total liabilities | $22.9B | $21.6B | $21.7B | $22.5B |
| Shareholders' equity | $28.6B | $29.9B | $26.7B | $25.9B |
Growth · year-over-year · Revenue CAGR -1.7%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | -0.3% | +0.8% | -5.6% | — |
| Net income growth | -6.1% | -1.7% | -15.1% | — |
| EPS growth | -6.1% | -1.5% | -15.2% | — |
| Free cash flow growth | -17.8% | +36.4% | -28.2% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: company filings via Yahoo Finance · DE · as of 2025-12-31. Figures in EUR; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.